2024年6月，安徽安科生物工程（集团）股份有限公司（简称“安科生物”）召开股东大会，正式选举宋礼华为公司新任董事长。宋礼华作为公司创始人之一，长期担任公司核心管理职务，在生物医药领域拥有丰富经验与深厚技术背景。此次接任董事长，标志着安科生物在战略发展和治理结构上迈入新阶段。安科生物成立于1995年，是中国领先的生物医药企业，专注于基因工程药物、肿瘤免疫治疗、细胞治疗等前沿领域的研发与产业化。宋礼华自公司创立以来，始终致力于推动技术创新和产品转化，主导了多个国家级重大科研项目，并成功将多款创新药推向市场。分析人士指出，宋礼华的再次掌舵，有助于公司在当前生物医药行业竞争加剧、政策环境变化的背景下，进一步聚焦核心业务、优化研发管线、提升运营效率。同时，其深厚的行业积淀和战略眼光，也将为安科生物加速国际化布局、拓展合作生态提供有力支撑。未来，安科生物有望在宋礼华的带领下，持续强化自主创新能力建设，深化产学研协同，推动高质量发展，为中国生物医药产业的升级贡献力量。
In June 2024, Anhui Anke Biotechnology (Group) Co., Ltd. (hereinafter referred to as ‘Anke Bio’) held a shareholders’ meeting and officially elected Song Lihua as its new Chairman of the Board. As one of the company’s founders, Mr. Song has long held key executive roles and possesses extensive experience and deep technical expertise in the biopharmaceutical sector. His appointment marks a new phase in Anke Bio’s strategic development and corporate governance.Founded in 1995, Anke Bio is a leading Chinese biopharmaceutical company focused on the research, development, and commercialization of gene-engineered therapeutics, cancer immunotherapies, and cell-based therapies. Since its inception, Mr. Song has been instrumental in driving technological innovation and product translation, leading multiple national-level research initiatives and successfully bringing several innovative drugs to market.Industry analysts note that Mr. Song’s return to the helm will help the company sharpen its focus on core business areas, optimize its R&D pipeline, and enhance operational efficiency amid intensifying competition and evolving regulatory landscapes in the biopharma industry. His profound industry knowledge and strategic vision are also expected to accelerate Anke Bio’s international expansion and strengthen its collaborative ecosystem.Under Mr. Song’s leadership, Anke Bio is poised to further bolster its independent innovation capabilities, deepen industry-academia-research collaboration, and contribute meaningfully to the advancement of China’s biopharmaceutical sector.
原创文章，作者：admin，如若转载，请注明出处：https://ktez.cn/5559.html